Previous Study: TRIO035
Next Study: TRIO032

Studies & Results


A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (CLEE011O12301C - New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE)

View FDA Study View EU Study

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at